Signal2026-07-15
ClinicalTrials.gov

[PHASE2] Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

Part of

Molecular Profiling In Endocrine Neoplasms

Open primary sourceSee the whole picture